Multiple myeloma (MM) is a progressive B-lineage neoplasia characterized by the accumulation of slow proliferative malignant plasma cells in the bone marrow compartment where the microenvironment seems to be favorable for their growth and survival. Heparan sulfate proteoglycans such as syndecan-1 and CD44 are thought to play a central role in the survival signals provided by these bone marrow survival niches, which require complex interactions between myeloma cells, extracellular matrix, stromal cells and soluble factors. In this report, we demonstrate that interleukin-6 (IL-6), the main survival and growth factor for myeloma cells, strongly increases CD44 gene expression. In addition, we show that IL-6 modulates CD44 RNA alternative splicing and induces the overexpression of all CD44 variant exons. Finally, we show that IL-6-induced CD44 cell surface molecules have a functional polarized membrane distribution. As IL-6 secretion induced from bone marrow stromal cells by myeloma cells is partly mediated through direct cell-to-cell interaction involving CD44 adhesion molecules, our findings suggest that a CD44/IL-6 amplification loop plays a crucial role in myeloma cell survival.
Introduction
Originating from a postswitch memory B cell or plasma cell compartment in peripheral lymphoid tissues, malignant myeloma cells accumulate in the bone marrow where the microenvironment seems to be favorable for their growth and survival. [1] [2] [3] [4] Interleukin-6 (IL-6), which is mainly produced by the stromal environment, is the major survival and growth factor for myeloma cells, both in vitro and in vivo. [5] [6] [7] [8] [9] Accordingly, myeloma cells spontaneously express IL-6 receptor (IL-6R), and both IL-6 and soluble IL-6R serum levels are correlated with the disease activity. 10, 11 Furthermore, IL-6 promotes the proliferation of freshly expanded human myeloma cells in vitro, 6 and anti-IL-6 monoclonal antibodies inhibit myeloma cell growth both in vitro and in vivo. 12, 13 Finally, IL-6 prevents apoptosis of myeloma cells induced by serum starvation or dexamethasone, 8 and Fas. 5 However, IL-6 alone is not sufficient to ensure myeloma cell survival. In addition, long-term in vitro culture of primary plasma cells requires stromal cell feeder layers for their survival, demonstrating the central role of bone marrow microenvironment in myeloma cell survival.
14 Indeed, it is now well established that the survival and proliferation of myeloma cells are dependent on soluble factors and physical interactions between malignant cells and both the stromal cells and the bone marrow extracellular matrix (ECM).
1,2-4 Different adhesion molecules such as the integrin family and CD44 have been involved in these interactions. [15] [16] [17] [18] [19] [20] [21] The CD44 gene contains 20 exons: 10 standard exons (1s-10s) encode for the so-called hematopoietic or standard isoform (CD44s), which is widely distributed and highly expressed on hematopoietic cells: 10 variant exons (1v-10v) give rise, by alternative splicing, to the formation of CD44 variant isoforms (CD44v) characterized by the addition of extracellular membrane-proximal domains in various combinations. 22 The expression of the CD44v isoform is highly restricted and associated with specific processes such as leukocyte activation or malignant transformation. 23 In multiple myeloma (MM), both normal and malignant plasma cells express CD44s, while some CD44v isoforms are differentially expressed on bone marrow plasma cells from normal individuals and myeloma patients. 24, 25 In particular, CD44v9 containing isoforms are associated with progressive disease and a short overall survival, suggesting that specific expression of some CD44v isoforms are critical for myeloma aggressiveness. 24, 26, 27 In addition, CD44v10 and CD44v6 expressions are involved in the selective homing of myeloma cells in the bone marrow. 28, 29 More recently, it was documented that abnormally low or high serum levels of hyaluronan (HA), the main ligand for CD44, 30 were associated with a poor prognosis in MM. 31 In addition, the increase in HA synthesis was described in bone marrow mesenchymental progenitor cells of patients with MM. 32 Adhesion molecules can also modulate the secretion and biological activity of cytokines. Indeed, myeloma cell-induced IL-6 production by stromal cells requires cell-to-cell interaction mediated by the cell surface molecules CD56/NCAM, VLA-4, VLA-5, LFA-1 and CD44. 15, 17, 18 In particular, the expression of the CD44v9 isoforms on myeloma cells seems to be required for this interaction. 24 As this cellular contact was partly inhibited by monoclonal antibodies against CD44, these data strongly suggest the implication of CD44 in the abnormally high levels of IL-6 found in the stromal microenvironment of MM patients with active disease. 17 Moreover, some adhesion molecules, especially proteoglycans with heparan sulfate (HS) side chains like syndecan-1 and some CD44 variant isoforms, are able to bind and potentiate the biological activity of heparin binding proteins such as insulin-like growth factor (IGF-1), 33 FGF, 34 HGF 35 or HB-EGF, 36, 37 which are survival and growth factors for myeloma cells. 38 Likewise, we have recently demonstrated that HA induces survival and proliferation of human myeloma cells by potentiating the IL-6 autocrine loop. 4, 39 All these data further underline the potential role of CD44 in the physiopathology of MM.
Based on these observations and to further elucidate the interplay between IL-6 and CD44, we analyzed the modulation of CD44 expression by IL-6 using IL-6-dependent human myeloma cell lines. 40 We demonstrate that IL-6 strongly upregulates CD44 cell surface expression and modulates the alternative splicing of CD44 mRNA. Furthermore, we show that the IL-6-induced CD44 molecules retain their functional polarized membrane expression. Altogether, our findings provide new insights into the complex interplay between myeloma cells and their microenvironment providing survival niches in the bone marrow, and further underline the relevance of IL-6-targeted therapeutics in MM.
Materials and methods

Cell cultures
XG-2, XG-6, XG-7, U266 and RPMI8226 human myeloma cells were obtained from Dr B Klein (Montpellier, France). The XG cell lines, whose survival and growth are completely dependent on addition of exogenous IL-6, were cultured in the presence of 2 ng/ml of recombinant human IL-6 (Sandoz, Vienna, Austria) in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). The IL-6-independent U266 and RPMI8226 cell lines were cultured in the same medium without IL-6.
Antibodies
Fluorescein-conjugated monoclonal anti-CD44 antibody (CD44-FITC, clone J-173) was purchased from Immunotech, France. Biotinylated monoclonal anti-syndecan-1 antibody (Mi15-biot) was obtained from Dr B Klein.
Detection of apoptotic cells
Apoptotic cells were detected using the fluorescein isothiocyanate-labelled annexin V method (FITC-annexin-V, Boehringer Mannheim). Annexin V has a high affinity for phosphatidylserine present on the outer cytoplasmic membrane of apoptotic cells. 41 Cells were washed, labelled with Annexin-V-Fluos according to the manufacturer's recommendations and analyzed by flow cytometry.
Flow cytometry analysis
The expression of CD44 molecules on living cells was quantified by double immunofluorescence staining using CD44-FITC and Mi15-biot monoclonal antibodies (mAbs). A total of 5 Â 10 5 cells were washed twice with phosphatebuffered saline (PBS) supplemented with 1% (v/v) FBS. The cells were resuspended in 50 ml of PBS-1% FBS containing CD44-FITC and Mi15-biot mAbs, and incubated for 45 min at 41C. The cells were then washed twice in PBS, and incubated for 45 min with streptavidin coupled to the peroxidase. After two additional washings, the cells were resuspended in 400 ml of PBS and fluorescence analysis was performed with a FACScan fluorescence activated cell sorter (Becton Dickinson), as previously described. 39 The cell preparations were analyzed by size, and 10 4 cells were evaluated for the percentage of positive cells and their fluorescence intensity. The binding of HA on myeloma cells was quantified by direct immunofluorescence staining using a fluorescein-conjugated anti-CD44 mAb obtained from Dr M-S Sy. 42 
Immunofluorescence analysis
Cells were collected by centrifugation, resuspended in PBS, plated on polylysine-coated slides, and then fixed 5 min in PBS containing 3.7% formaldehyde. CD44 was detected by direct immunofluorescence using the CD44-FITC mAb (dilution 1:200). Slides were viewed using a Leika microscope and image files were processed with the Adobe Photoshop program.
RT-PCR analysis
Total RNAs were isolated as previously described 43 and cDNAs were prepared from 1 mg of RNA by using Superscript reverse transcriptase (Life Technologies, Pontoise, France) according to the manufacturer's instructions. For a semiquantitative approach, CD44 cDNAs were amplified by polymerase chain reaction (PCR), using the forward primer GCACAGACA-GAATCCCTGCTACC located in exon 5 and the following reverse primers located in the different variable exons (v): 2v (exon 6) CAGCCATTTGTGTTGTTGTG; 3v (exon 7) TGGTGCTGGAGATAAAATCT; 4v (exon 8) CAGT-CATCCTTGTGGTTGTC; 5v (exon 9) TTGTGCTTGTA-GAATGTGGG; 6v (exon 10) CAGCTGTCCCTGTTGTCGAA; 7v (exon 11) CCATCCTTCTTCCTGCTTGA; 8v (exon 12) GCGTTGTCATTGAAAGAGGT; 9v (exon 13) TGCTTGATGT-CAGAGTAGAA; 10v (exon 14) CTGATAAGGAACGATTGACA, listed 5 0 to 3 0 as previously described. 44 For global CD44 isoforms expression analysis, the cDNAs were amplified using the forward primer GCACAGACAGAATCCCTGCTACC located in exon 5 and reverse primer CCAAGATGATCAGCCATTCTGG located in exon 17. GAPDH used as an invariant control was PCR amplified with the forward (TGAAGGTCGGAGTCAACG-GATTTGGT) and reverse: (CATGTGGGCCATGAGGTCCAC-CAC) primers. A total of 23 cycles of PCR were realized in the presence of [ 32 P]-dCTP, and the PCR products were analyzed on a sequencing gel prior to autoradiography.
Statistical analysis
The statistical significance of the data was evaluated by using Student's t-test for pairs.
Results
IL-6 controls CD44 cell surface expression on human myeloma cells
To investigate the effect of IL-6 on CD44 membrane expression, XG-2 and XG-6 human myeloma cell lines, whose survival and proliferation are dependent on the addition of exogenous IL-6, 40 were starved of IL-6 and then cultured with or without IL-6 for 3 days. CD44 cell surface expression was assessed by flow cytometry analysis with a double staining method using anti-CD44 mAb conjugated to fluorescein (CD44-FITC) and phycoerythrin-conjugated anti-syndecan-1 mAb (MI15-biot). As syndecan-1 antigen is rapidly lost by myeloma cells undergoing apoptosis, 45 this approach allowed us to determine the level of CD44 membrane expression on living myeloma cells (syndecan-1 positive cells), and to exclude cells that have been engaged throughout a cell death program (syndecan-1 negative cells). Indeed, it is well established that apoptotic processes are associated with a reduction in cell surface expression of some molecules. 46, 47 A typical experiment performed the XG-6 cell line is presented in Figure 1a . CD44 cell surface expression, evaluated by the mean of fluorescence intensity (MFI) on living cells (upper right quadrant in each dot plot), was strongly reduced in the absence of IL-6 (MFI ¼ 162) vs presence of IL-6 (MFI ¼ 567). This experiment was reproduced several times on XG-6 and XG-2 cell lines with average reductions of 71.3% and 41.6%, respectively (Figure 1b) . The statistical significance of these experiments is presented in Figure 1b . Time course analysis performed on the XG-6 cell line revealed that CD44 CD44 modulation by IL-6 T Vincent and N Mechti expression was promptly downregulated (28% reduction after 8 h of depletion) in a time-dependent manner ( Figure 2a ). This mechanism was reversible because the level of CD44 expression was completely and rapidly restored when IL-6 was reintroduced into the culture medium (Figure 2b ). Interestingly, in U266 and XG-7 cell lines, which the survival is, respectively, entirely and partly IL-6 independent, a less important but significant decrease in CD44 expression was observed (27.4% and 27.3%, respectively), suggesting that the regulation of CD44 and myeloma cell survival by IL-6 used distinct pathways (data not shown).
To completely ascertain that the reduction of CD44 expression observed in IL-6-starved myeloma cells did not result from early apoptotic processes, we used the ability of human alpha interferon (Hu-a2aIFN) to antagonize apoptosis induced in IL-6-dependent myeloma cells by the removal of IL-6. 48 XG-6 cells were starved of IL-6 and then cultured 3 days in the presence of 200 UI/ml of Hu-a2aIFN. The percentage of apoptotic cells and the level of CD44 cell surface expression were quantified, as previously described. Although apoptosis induced by IL-6 starvation was strongly antagonized by Hu-a2aIFN (Figure 3a) , the reduction of CD44 expression was similar in the presence or absence of Hu-a2aIFN (Figure 3b ). In addition, no significant modification in the expression of CD44 by Hu-a2aIFN was observed on cells cultured in the presence of IL-6 (data not shown). Altogether, these data clearly demonstrated that the upregulation of CD44 expression by IL-6 on myeloma cells is independent of apoptotic processes.
IL-6 controls CD44 expression at the transcriptional level
To determine whether the regulation of CD44 cell surface expression was associated with an alteration of CD44 gene expression, the level of CD44 mRNA was monitored by semiquantitive RT-PCR analysis. Using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an invariant control, equal amounts of cDNA were used for the analysis of CD44 mRNA. As shown in Figure 4 , the amount of CD44 mRNA was strongly reduced in XG-6 cells starved of IL-6. RPMI8226 myeloma cell line, which does not express CD44, was used as a negative control. These data demonstrated that IL-6 upregulates CD44 expression at the transcriptional level.
IL-6-induced CD44 molecules have a polarized membrane organization
A proportion of myeloma cells are polarized with a uropod on one end and a lamelipodia on the other end. 49 Several cell surface molecules such as syndecan-1, CD54 and CD44 localize specifically to the uropod where they promote adhesion, intercellular communication, and concentration and presentation of heparin binding cytokines. 49 As polarized organization of heparan sulfate proteoglycans (HSPGs) seems to play a major role in cellular communication and signalling, we evaluated whether IL-6 could influence the polarized CD44 modulation by IL-6 T Vincent and N Mechti membrane organization of CD44 cell surface molecules. To this aim XG-6 cells were starved of IL-6 and then cultured for 3 days in the presence or absence of exogenous IL-6. Cell surface CD44 distribution was analyzed by direct immunofluorescence with a fluorescein-conjugated anti-CD44 antibody, as described in Materials and methods. We observed that, in the absence of IL-6, XG-6 cells exhibited a polarized phenotype with a striking localization of CD44 molecules on membrane protrusions ( Figure 5 ). This membrane distribution was not altered during IL-6-induction of CD44 expression.
IL-6 does not modulate the binding of HA to CD44
Although CD44 is widely expressed, only a few cells bind HA constitutively. 50 . In addition, binding of HA to CD44 can be altered by cellular differentiation, inside/out signalling and extracellular stimuli. 51 Previous studies have identified TNFa as a positive regulator, and IL-4 and IL-13 as negative regulators of HA binding to CD44. 50, 52, 53 To determine whether IL-6 could regulate CD44 affinity to HA, we compared HA binding and CD44 expression on several myeloma cell lines cultured in the presence or absence of exogenous IL-6. HA binding was quantified by direct immunofluorescence staining using fluorescein-conjugated HA (HA-FITC), as previously described. 4 As shown in Figure 6 , no correlation was observed between the level of CD44 expression and the ability of cells to bind HA. Indeed, XG-6 and U266 cell lines that express a high level of CD44 molecules did not bind, or bound weakly to HA-FITC. Conversely, XG-2 and XG-7 cell lines strongly bound HA-FITC. Interestingly, IL-6 increased both binding of HA and CD44 expression on XG-2 and XG-7 cells in similar proportions, whereas it failed to increase binding of HA on XG-6 and U266 cell lines. RPMI8226, which does not express CD44 and does not bind HA-FITC, was used as a negative control (data not shown). Taken together, these data demonstrated that IL-6 did not influence HA binding on human myeloma cells.
IL-6 modulates CD44 alternative splicing
In addition to the CD44 standard molecule (CD44s), alternative splicing of one or more variable exons (1v-10v) results in the potential creation of a large number of CD44v molecules that are involved in the physiopathology of MM. [25] [26] [27] [28] [29] We decided to investigate whether the expression of the different CD44v isoforms could be influenced by IL-6. Using specific primers for each variant exon, the mRNA of the different CD44v isoforms was analyzed by semiquantitive RT-PCR on XG-6 cells cultured in the presence or absence of exogenous IL-6 for 48 h. GAPDH was used as an invariant control to ensure that equal amounts of cDNA were used. As shown in Figure 7 , all variant exons were markedly overexpressed in the presence of IL-6. Some isoforms appeared only expressed in the presence of IL-6. Conversely, especially in exons v5 and v8 containing isoforms, some CD44 variants were overexpressed in the absence of exogenous IL-6. Clearly, IL-6 not only upregulated CD44 gene expression but also strongly modulated the alternative splicing 
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Discussion
Some recent reports point to the existence of long life plasma cells that have the capacity to live for unlimited time if rescued by specific factors provided in survival niches. 54 Like their physiological counterpart, malignant plasma cells specifically localize in the bone marrow of patients with MM where the microenvironment seems to be favorable for their growth and survival. [1] [2] [3] [4] 39 Survival signals provided in these niches require complex interactions between myeloma cells, bone marrow stromal cells, ECM and soluble factors. In particular, IL-6 secretion induced from bone marrow stromal cells by myeloma cells is mediated through direct cell-to-cell contacts involving adhesion molecules such as integrins and CD44. 15, 17, 18 In this report, we show that IL-6 strongly induces CD44 cell surface expression on myeloma cells. These data suggest the existence of a CD44/IL-6 amplification loop in which stromal cells induce CD44 expression on myeloma cells through IL-6 and, in turn, myeloma cells induce IL-6 secretion by stromal cells through CD44 molecules. Furthermore, it has been reported that IL-6 Total RNAs were isolated for each experimental condition and cDNAs were prepared as described in Materials and methods, and amplified by PCR, using specific CD44 (exon 5 and exon 17) and GAPDH primers. A total of 23 cycles of PCR were performed in the presence of [ 32 P]-dCTP, and the PCR products were fractionated on a sequencing gel prior to autoradiography.
Figure 5
Polarized organization of CD44 cell surface protein. XG-6 cells were cultured for 72 h in the presence or absence of IL-6. CD44 cell surface expression was detected by direct immunofluorescence with CD44-FITC mAb. Slides were viewed using a Leika microscope and image files were processed with the Adobe Photoshop program. CD44 modulation by IL-6 T Vincent and N Mechti binds soluble HS, suggesting that it can bind HS side chains of some proteoglycans like syndecan-1 and CD44. [55] [56] [57] Such a binding is proposed to potentiate its biological activity by sequestrating and concentrating IL-6 near its site of secretion, and thus favoring its autocrine or paracrine activity. 38 HS proteoglycans can also act as coreceptors for growth factors by the formation of a ternary complex mediated by specific interactions of the HS side chain with both the growth factor and its receptor, resulting in an increase in receptor dimerization and cell signalling. 35, 38, 58, 59 This process is enhanced by the expression of CD44 variants, especially CD44v3 or CD44v6 isoforms, which contain additional domains that support the covalent attachment of glycosaminoglycan side chains. 60, 61 The fact that IL-6 induces the overexpression of all CD44 variant exons on myeloma cells provides a higher level of interaction between soluble factors and adhesion molecules by increasing the number of potential heparan binding proteins (HBPs) binding sites. Other variant exons can play an important role in the physiopathology of MM. In particular, CD44v10 and CD44v6 isoforms have been involved in the adhesive interaction between myeloma cells and the bone marrow endothelial and stromal cells, respectively, leading to the selective homing of myeloma cells to the bone marrow compartment. 28, 29 CD44v9 is involved in IL-6 secretion induced from bone marrow stromal cells by adhesion to myeloma cells, 25 and its overexpression is associated with progressive diseases and a short overall survival in MM. 26, 27 These data and our report strengthen the idea that IL-6-induced overexpression of CD44 variant exons might be critical for in vivo myeloma cell growth and survival, in particular in the earlier stage of the disease, where long-term in vitro culture of primary plasma cells requires stromal cell feeder layers for their survival.
14 Recently, glucocorticoid-induced drug resistance of RPMI8226 human myeloma cells was correlated with an increased expression of the a-isoform of the glucocorticoid receptors, and specific modulations in CD23, CD38, CD44 and CD58 cell surface expressions. 62 In particular, the prednisone and dexamethasoneresistant cells strongly overexpressed CD44, suggesting that CD44 could contribute in the development of drug resistance.
Myeloma cells are characterized by a polarized membrane organization shown to be crucial for both cell adhesion and cellto-cell communication. In addition, the migratory potential of myeloma cell lines was correlated to their high number of polarized cells. 49 Interestingly, most HS proteoglycans are localized to the uropod of myeloma cells. 49 This cell surface organization leads to the concentration of HBPs to this pole and favors their presentation to target cells. The fact that IL-6-induced CD44 molecules have a functional polarized membrane organization indicates that IL-6, by increasing the HBPs binding potential of uropod, might potentiate the biological activity of HBPs such as IGF-1, 33 FGF, 34 HGF 35 or HB-EGF, 36, 37 which are survival and growth factors for myeloma cells. 38 In the same way, it has recently been shown that some CD44 isoforms can act as a cell surface docking receptor for active matrix metalloproteinase-9, and promote ECM degradation. 63, 64 Retention of matrix metalloproteinases on the cell surface by polarized CD44 molecules leads to the concentration of proteolytic activity at the point of contact between the cells and the ECM, and provides a mechanism for CD44-mediated tumor cell invasion.
HA is thought to play a role in the physiopathology of MM. 4, 31, 32, 39 Nevertheless, in accordance with previous studies,
Figure 7
Analysis of the different CD44 variant isoforms expressed on XG-6 myeloma cells. XG-6 cells were cultured for 72 h in the presence ( þ ) or absence (À) of IL-6. Total RNAs were isolated for each experimental condition and cDNAs were prepared and amplified by PCR, using specific CD44 primers located in the different variant exons (v2-v10), as described in Materials and methods. A total of 23 cycles of PCR were performed in the presence of [ 32 P]-dCTP, and the PCR products were fractionated on a sequencing gel prior to autoradiography. The molecular weights are indicated.
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T Vincent and N Mechti we did not observe any correlation between CD44 membrane expression and the binding of HA. Particularly, XG-6 and U266 cell lines, which highly expressed CD44, did not bind HA-FITC efficiently. In addition, IL-6 did not increase CD44/HA affinity significantly, and failed to induce HA binding on XG-6 and U266 cell lines. Accordingly, we have previously shown that HA acts as a growth and survival factor for human myeloma cells through a CD44-independent pathway. 4, 39 Indeed, HA is able to potentiate autocrine and/or paracrine cytokine activities very similarly to HSPG side chains. So, it is tempting to speculate that HSPGs and HA act synergistically by concentrating, protecting and presenting different active molecules. In other pathological models, some growth factors such as the IGF-1 were reported to increase CD44 expression. 44, 65, 66 Interestingly, in vivo induction of IGF-1 receptor and CD44v6 expressions induced on myeloma by the bone marrow microenvironment have been shown to confer homing and adhesion to murine myeloma cells. 28 As IGF-1 is a growth and survival factor in MM 67 and binds HS, 33 these data strongly suggest that other growth factors or cytokines may act synergistically with IL-6 to amplify the CD44/IL-6 loop. Further investigations are needed to clarify this point.
IL-6 has been described as the major survival and growth factor for human myeloma cells, both in vitro and in vivo. The demonstration that IL-6 can modulate expression and alternative splicing of CD44 in malignant plasma cells provides new insights on the pleiotropic activities of this cytokine and further underline the relevance of IL-6-targeted therapeutics in MM. Alternatively, our finding on the existence of a CD44/IL-6 amplification loop may provide the rationale for the development of therapies targeting CD44. Indeed, the ligation of CD44 with specific mAbs inhibits the proliferation of acute myeloid leukemia cells by stabilizing the cyclin-dependent kinase inhibitor p27(Kip1) protein, resulting in inhibition of the cyclin E/Cdk2 kinase activity. 68 Accordingly, we have previously reported that a high level of p27(Kip1) protein expression was associated with the inhibition of myeloma cells proliferation. 4 The fact that some CD44v isoforms are preferentially expressed on tumor cells clearly provides a most selective alternative to target tumor cells. For example, the anti-CD44v6 antibodies have been successfully used to block tumor growth and metastasis of an adenocarcinoma in an animal model. 69, 70 In MM, the involvement of CD44v6 and CD44v10 in the homing of myeloma cells in the bone marrow, and the involvement of CD44v9 in the CD44/IL-6 amplification loop, provide interesting targets for the development of new therapeutics. Finally, our findings highlight the complex interplay between myeloma cells, bone marrow stromal cells, ECM and soluble factors in order to provide an optimal microenvironment for myeloma cell growth and survival in bone marrow survival niches.
